AzTrials
AzTrials

Chronic Lymphocytic LeukemiaPhase 3NCT00090051

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

A Phase 3 study testing Rituximab, Fludarabine Phosphate and Cyclophosphamide in people with Chronic Lymphocytic Leukemia, run by Hoffmann-La Roche at 106 sites in 17 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Chronic Lymphocytic Leukemia
What is being tested?
Rituximab, Fludarabine Phosphate and Cyclophosphamide
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
552 participants
Where
106 sitesin 17 countries
Study dates
31 Jul 2003to 31 May 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years
  • Established diagnosis of B-cell CLL by NCI Working Group criteria
  • ≤1 previous line of chemotherapy
  • Expected survival >6 months
  • Acceptable hematologic status, liver function, renal function, and pulmonary function
  • Negative serum pregnancy test for both pre-menopausal women and for women who are < 2 years after the onset of menopause
  • Written informed consent

Who cannot join

  • Prior treatment with interferon, rituximab or other monoclonal antibody
  • Prior allogeneic bone marrow transplant (BMT) or autologous BMT or peripheral stem cell transplant (PBSCT) or patients who are considered to be candidates for allogeneic or autologous BMT or PSCT as assessed by their treating physician
  • Fertile men or women of childbearing potential not using adequate contraception
  • Severe Grade 3 or 4 non-hematological toxicity or prolonged (> 2 weeks) Grade 3 or 4 cytopenia on prior fludarabine or nucleoside analogue regimen
  • History of fludarabine-induced or clinically significant autoimmune cytopenia
  • History of other malignancies within 2 years prior to study entry, except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low-grade early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent.
Show all 17Show fewer
  • Medical conditions requiring long term use (> 1 month) of systemic corticosteroids
  • Active bacterial, viral, or fungal infection requiring systemic therapy
  • Severe cardiac disease
  • Seizure disorders requiring anticonvulsant therapy
  • Severe chronic obstructive pulmonary disease with hypoxemia
  • Uncontrolled diabetes mellitus or hypertension
  • Transformation to aggressive B-cell malignancy.
  • Known infection with HIV, HCV, or hepatitis B
  • Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study
  • Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
  • Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Trial locations and contacts

106 sites in 17 countries.

106 sites in 17 countries

France19 sites

  • Hopital Avicenne; Hematologie Biologique

    Bobigny, 93009

  • Hopital Clemenceau; Hematologie Clinique

    Caen, 14033

  • Chu Estaing; Hematologie Clinique Adultes

    Clermont-Ferrand, 63003

  • Hopital Henri Mondor; Hematologie Clinique

    Créteil, 94010

  • Clinique Victor Hugo; Chimiotherapie

    Le Mans, 72015

  • Hopital Claude Huriez; Hematologie

    Lille, 59037

  • Hopital Edouard Herriot; Bat.E-Hematologie

    Lyon, 69003

  • Centre Leon Berard; Departement Oncologie Medicale

    Lyon, 69373

  • Institut J Paolii Calmettes; Onco Hematologie 1

    Marseille, 13273

  • Hôpital Lapeyronie; Hématologie Oncologie Médicale

    Montpellier, 34295

  • Hopital Hotel Dieu Et Hme;Hopital De Jour

    Nantes, 44093

  • Hotel Dieu; Hematologie- Oncologie

    Paris, 75181

  • Inserm Cic 9504

    Paris, 75475

  • Hopital Pitie Salpetriere; Hematologie Clinique

    Paris, 75651

  • Ch Lyon Sud; Hemato Secteur Jules Courmont

    Pierre-Bénite, 69495

  • Chu La Miletrie; Hdj Cons Hemato Cancerologie

    Poitiers, 86021

  • Centre Henri Becquerel; Hematologie

    Rouen, 76038

  • Hopital Bretonneau; Clinique D'Oncologie & de Radiotherapie

    Tours, 37044

  • Hopitaux De Brabois; Hematologie Medecine Interne

    Vandœuvre-lès-Nancy, 54511

Other trials in France

Italy10 sites

  • Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica

    Bari, Apulia, 70124

  • A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna

    Bologna, Emilia-Romagna, 40138

  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia

    Milan, Lombardy, 20162

  • A.O. Universitaria Federico II Di Napoli; Oncologia Ed Endocrinologia Clinica

    Naples, Campania, 80131

  • Irccs Policlinico San Matteo; Divisione Di Ematologia

    Pavia, Lombardy, 27100

  • Ospedale S. Eugenio; Divisione Di Ematologia

    Rome, Lazio, 00144

  • Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo

    Rome, Lazio, 00152

  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia;Dip. Biotecnologie Cel CELLULARI ED EMATOLOGIA

    Rome, Lazio, 00161

  • IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo

    San Giovanni Rotondo, Apulia, 71013

  • Ospedale Di Vicenza; Nefrologia, Ematologia

    Vicenza, Veneto, 36100

Other trials in Italy

Russia10 sites

  • N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis

    Moscow, 115478

  • Haematology Research Center; Haematology

    Moscow, 125167

  • City Clinical Botkin's Hospital; City Hematological Center

    Moscow, 125284

  • Medical Radiological Research Centre Rams; Dept. of Radiotherapy & Chemotherapy of Hemoblastosis

    Obninsk, 249036

  • Research Inst. Hematology /Blood Transfusion ; Hemablastosis, Supression Hemopoesis & B M Transplant

    Saint Petersburg, 193024

  • Regional Clinical Hospital; Hematology Dept. #2 For B M Transplantation & High Dose Chemo.

    Saint Petersburg, 194291

  • Pavlov State Medical Uni ; Bone Marrow Transplantation Clinic

    Saint Petersburg, 197022

  • S.-Peterburg Pavlov State Medical University ; Haematology

    Saint Petersburg, 197022

  • State Medical Inst. Municipal Hospital #31; Oncology & Hematology Dept. With the Usechemo. in Adult

    Saint Petersburg, 197110

  • Regional Clinical Hospital N.A. Kalinin; Hematology Dept

    Samara, 443095

Other trials in Russia

United Kingdom10 sites

  • Royal Bournemouth General Hospital; Haematology

    Bournemouth, BH7 7DW

  • Addenbrookes Hospital; Haematology

    Cambridge, CB2 0QQ

  • Stobhill Hospital; Dept of Haematology

    Glasgow, G83 8NG

  • Leeds General Infirmary; Medicine

    Leeds, LS1 3EX

  • Leicester Royal Infirmary; Dept of Haematology

    Leicester, LE1 5WW

  • Royal Liverpool Uni Hospital; Haematology

    Liverpool, L7 8XP

  • St. Bartholomew'S Hospital; Dept of Medical Oncology

    London, EC1A 7BE

  • King'S College Hospital; Haematology

    London, SE5 9RS

  • Royal Marsden Hospital; Academic Dept of Haematology

    Sutton, SW3 6JJ

  • Pinderfields General Hospital; Dept of Haematology

    Wakefield, WF1 4DG

Other trials in United Kingdom

Canada9 sites

  • Uni of Alberta Hospital

    Edmonton, Alberta, T6G 2R7

  • QEII HSC; Oncology

    Halifax, Nova Scotia, B3H 2Y9

  • Hamilton Health Sciences - Juravinski Cancer Centre; Hematology

    Hamilton, Ontario, L8V 5C2

  • Mcgill University - Royal Victoria Hospital; Oncology

    Montreal, Quebec, H3A 1A1

  • The Ottawa Regional Hospital - General Campus; Division of Hematology, Box 704

    Ottawa, Ontario, K1H 1C4

  • Health Science Centre

    St. John's, Newfoundland and Labrador, A1B 3V6

  • Sunnybrook Odette Cancer Centre

    Toronto, Ontario, M4N 3M5

  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept

    Toronto, Ontario, M5G 2M9

  • BCCA-Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6

Other trials in Canada

Hungary7 sites

  • Szent Laszlo Hospital; Hematology Dept

    Budapest, 1097

  • National Institute of Oncology, A Dept of Internal Medicine

    Budapest, 1122

  • Országos Gyógyintézeti Központ; Haematologiai Osztaly

    Budapest, 1135

  • Uni of Debrecen; 2Nd Clinic of Internal Medicine

    Debrecen, 4004

  • University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology

    Debrecen, 4032

  • Uni of Pecs; Dept of Internal Medicine

    Pécs, 7624

  • University of Szeged, II Dept of Internal Medicine

    Szeged, 6720

Other trials in Hungary

United States6 sites

  • Uab Comprehensive Cancer Center

    Birmingham, Alabama, 35294-3300

  • Rush-Presbyterian St. Luke'S Medical Center

    Chicago, Illinois, 60612

  • Duke University Medical Center

    Durham, North Carolina, 27710

  • Pacific Coast Hematology/Oncology Medical Group

    Fountain Valley, California, 92708

  • California Cancer Center Woodward Park; Community Medical Centers

    Fresno, California, 93720

  • Milton S. Hershey Medical Center; Penn State Cancer Inst.

    Hershey, Pennsylvania, 17033

Other trials in United States

Poland6 sites

  • Medical University School; Dept. of Haematology

    Lodz, 93-510

  • Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie

    Lublin, 20-081

  • Akademii Medycznej W; Klinika Hematologii

    Poznan, 02-097

  • Klin. Chorob Wewnetrznych I Hemat. Z Osrodkiem Transplant. Szpiku

    Warsaw, 00-909

  • Instytut Hematologii I Transfuzjologii; Klinika Chorob Wewnetrznych I Hematologii

    Warsaw, 00-957

  • Samodzielny Publiczny Centralny Szpital Kliniczny; Haematology Dept.

    Warsaw, 02-097

Other trials in Poland

Spain5 sites

  • Hospital Universitario de la Princesa; Servicio de Hematologia

    Madrid, 28006

  • Hospital Univ. 12 de Octubre; Servicio de Hematologia

    Madrid, 28041

  • Hospital Clinico Universitario de Salamanca;Servicio de Hematologia

    Salamanca, 37007

  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

    Valencia, 46010

  • Hospital Universitario Miguel Servet; Servicio Hematologia

    Zaragoza, 50009

Other trials in Spain

Australia4 sites

  • Mater Hospital; Division of Cancer Services

    Brisbane, Queensland, 4101

  • Frankston Hospital; Oncology/Haematology

    Frankston, Victoria, 3199

  • Peter Maccallum Cancer Institute; Medical Oncology

    Melbourne, Victoria, 3000

  • Concord Repatriation General Hospital; Haematology

    Sydney, New South Wales, 2139

Other trials in Australia

Netherlands4 sites

  • Meander Mc, Locatie Lichtenberg; Dept of Lung Diseases

    Amersfoort, 3818 ES

  • Academisch Medisch Centrum Universiteit Amsterdam

    Amsterdam, 1105 AZ

  • Erasmus Mc - Daniel Den Hoed Kliniek; Medical Oncology

    Rotterdam, 3075 EA

  • Leyenburg Ziekenhuis; Haematology

    The Hague, 2545 CG

Other trials in Netherlands

Romania4 sites

  • Fundeni Clinical Inst. ; Hematology Dept

    Bucharest, 022328

  • Spitalul Clinic Coltea; Clinica de Hematologie

    Bucharest, 030171

  • Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie

    Târgu Mureş, 540136

  • Spitalul Clinic municipal de Urgenta Timisoara; Clinica de Hematologie

    Timișoara, 300079

Other trials in Romania

Belgium3 sites

  • ZNA Stuivenberg

    Antwerp, 2060

  • Institut Jules Bordet

    Brussels, 1000

  • UZ Leuven Gasthuisberg

    Leuven, 3000

Other trials in Belgium

New Zealand3 sites

  • Auckland city hospital; Auckland Regional Cancer Centre and Blood Service

    Auckland, 1023

  • Christchurch Hospital; Canterbury Health Laboratories

    Christchurch

  • Wellington Hospital; Regional Oncology Unit

    Wellington, 6002

Other trials in New Zealand

Denmark2 sites

  • Aarhus Universitetshospital, Hæmatologisk Afdeling R

    Aarhus, 8000

  • Righospitalet, Hæmatologisk Klinik

    København Ø, 2100

Other trials in Denmark

Norway2 sites

  • Haukeland Universitetshospital; Medicine Dept

    Bergen, 5021

  • Rikshospitalet Uni Hospital

    Oslo, 0027

Other trials in Norway

Sweden2 sites

  • Karolinska Inst. , Huddinge Uni Hospital; Depart. of Hematology

    Huddinge, 14186

  • Universitetssjukhuset i Linköping, Hematologkliniken

    Linköping, 581 85

Other trials in Sweden

About this study

Official title: Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL

The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.

Medical subject headings
Leukemia, Lymphocytic, Chronic, B-Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00090051
Study groupRoleWhat they receive
Fludarabine+Cyclophosphamide (FC)Active comparatorNot described
Receives: Drug: Fludarabine Phosphate; Drug: Cyclophosphamide
Fludarabine+Cyclophosphamide+Rituximab (FCR)ExperimentalNot described
Receives: Drug: Rituximab; Drug: Fludarabine Phosphate; Drug: Cyclophosphamide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

    Progression-free survival as assessed by the IRC was defined as the time between randomization and the date of first documented disease progression, relapse after response, or death from any cause, whichever came first. Patients without a PFS event were censored at their last tumor assessment date.

    Measured: Mean observation time at time of analysis was approximately 26 months

  2. Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC)

    Progression-free survival as assessed by the IRC was defined as the time between randomization and the date of first documented disease progression, relapse after response, or death from any cause (PFS events), whichever came first. Patients without a PFS event were censored at their last tumor assessment date.

    Measured: Mean observation time at time of analysis was approximately 26 months

  3. Final Analysis: Time to Progression-Free Survival Event

    Time to progression-free survival (PFS) event was defined as the time between randomization and the date of first documented PFS event: disease progression, relapse or death by any cause, whichever came first.

    Measured: Median observation time was approximately 5 years

Secondary outcomes (12)

  1. Overall Survival (OS)

    Overall survival was determined from the date of randomization to the date of death irrespective of cause. Patients who had not died at the time of the final analysis (clinical data cut-off) were censored at the date of the last contact.

    Measured: Mean observation time at time of analysis was approximately 26 months

  2. Number of Participants With Overall Survival (OS) Events

    Overall survival was determined from the date of randomization to the date of death (OS event) irrespective of cause. Patients who had not died at the time of the final analysis (clinical data cut-off) were censored at the date of the last contact.

    Measured: Mean observation time at time of analysis was approximately 26 months

  3. Event-free Survival (EFS)

    Event free survival was measured from the day of randomization to the date of first documented PD, relapse after response, start of a new treatment or death from any cause. Patients without an EFS event were censored at their last tumor assessment date.

    Measured: Mean observation time at time of analysis was approximately 26 months

  4. Number of Participants With Event-free Survival (EFS) Events

    Event free survival was measured from the day of randomization to the date of first documented Progressive Disease (PD), relapse after response, start of a new treatment or death from any cause (EFS events). Patients without an EFS event were censored at their last tumor assessment date.

    Measured: Mean observation time at time of analysis was approximately 26 months

  5. Disease-free Survival (DFS)

    Disease free survival was defined for all patients with a best overall response (BOR) of Complete Response (CR) and measured the time from first documented CR in a sequence of consecutive CRs until documented disease progression, relapse or death from any cause. Patients without a DFS event at the time of the analysis (clinical data cut-off) were censored at their last tumor assessment date.

    Measured: Mean observation time at time of analysis was approximately 26 months

  6. Number of Participants With Disease-free Survival (DFS) Events

    Disease free survival was defined for all patients with a best overall response (BOR) of Complete Response (CR) and measured the time from first documented CR in a sequence of consecutive CRs until documented disease progression, relapse or death from any cause (DFS events). Patients without a DFS event at the time of the analysis (clinical data cut-off) were censored at their last tumor assessment date.

    Measured: Mean observation time at time of analysis was approximately 26 months

  7. Final Analysis: Time to Overall Survival Event

    Overall survival (OS) was determined from the date of randomization to the date of death (OS event) irrespective of cause.

    Measured: Median observation time was approximately 5 years

  8. Final Analysis: Time to Event-Free Survival Event

    Event free survival (EFS) was defined as the time from the day of randomization to the date of first EFS event: documented disease progression, relapse after response, start of a new treatment or death from any cause.

    Measured: Median observation time was approximately 5 years

  9. Final Analysis: Percentage of Participants With Complete Response

    Complete response was defined as the disappearance of all signs of cancer in response to treatment.

    Measured: Median observation time was approximately 5 years

  10. Final Analysis: Time to Disease-Free Survival Event

    Time to disease-free survival (DFS) event was defined as the time from first documented response until the first documented DFS event: disease progression, relapse or death from any cause.

    Measured: Median observation time was approximately 5 years

  11. Final Analysis: Duration of Response

    Duration of response was defined as the time between the date of the earliest qualifying response and the date of disease progression or death due to any cause.

    Measured: Median observation time was approximately 5 years

  12. Final Analysis: Time to New Chronic Lymphocytic Leukemia (CLL) Treatment

    Time to new CCL treatment was defined as the time from randomization to the first day of new treatment for CCL or death.

    Measured: Median observation time was approximately 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2004 (estimated)
  2. Study start31 Jul 2003
  3. Primary completion23 Jul 2008
  4. Study completion31 May 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
552 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00090051
Sponsor's protocol ID
102-14
Other IDs
BO17072
Status last verified
Jul 2017
First submitted
23 Aug 2004
Last updated
1 Aug 2017
Data monitoring committee
Yes

Publications

  • Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Dohner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 17;124(3):420-5. doi: 10.1182/blood-2013-12-538975. Epub 2014 Jun 10.

    PubMed 24916506

  • Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, Benthaus T, Kakadia PM, Spiekermann K, Hiddemann W, Braess J, Truong S, Patten N, Wu L, Lohmann S, Dornan D, GuhaThakurta D, Yeh RF, Salogub G, Solal-Celigny P, Dmoszynska A, Robak T, Montillo M, Catalano J, Geisler CH, Weisser M, Bohlander SK. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood. 2013 May 2;121(18):3650-7. doi: 10.1182/blood-2012-10-458695. Epub 2013 Mar 22.

    PubMed 23525797

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Rituximab, Fludarabine Phosphate and Cyclophosphamide in people with Chronic Lymphocytic Leukemia, run by Hoffmann-La Roche at 106 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 106 sites in France, Italy, Russia, United Kingdom, Canada and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Jan 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC) (time frame: Mean observation time at time of analysis was approximately 26 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00090051, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2017.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in